BPC-157

What it is

BPC-157 is a lab-made chain of 15 amino acids. It is often described as "derived from" a protein in human gastric juice. The compound sold and studied is not that natural protein; it is a synthetic peptide that does not occur in the body in this form.

One lab did most of the work. Predrag Sikirić's group at the University of Zagreb produced the bulk of the animal literature over roughly two decades. A large paper count is less reassuring when the papers keep coming from the same place; independent replication is thin.

The popular story says BPC-157 was "legalized" in April 2026. Not exactly. FDA lifted a prohibition; it did not grant approval or blanket permission. (See Legal status.)

What humans actually show

• Animal studies: Many. Rodent models of tendon, ligament, muscle, and gut-lining injury report faster healing and better vascularization. Most come from or are closely tied to the Zagreb group, so independent replication remains limited.
• Human studies: One, essentially. A 2025 systematic review screened 544 papers and found a single human study: 12 people with chronic knee pain, no control group, no blinding. That is a case series, not a test that can establish whether BPC-157 caused the result. (Vasireddi et al., 2025)
• Clinical trials: The Phase 1 trial of the pharmaceutical formulation (PCO-02 / Bepecin) for inflammatory bowel disease was cancelled and never published. (NCT02637284)
• What has NOT been studied in humans: Long-term safety. Tendon repair, despite that being the headline claim. Effects in specific populations. Drug interactions. Formulation or route. The July FDA review is scoped to ulcerative colitis, not the injury-recovery use driving the online story.

The recurring trap in this category is conflating "newly compoundable" with "newly studied." Nothing about the 2026 regulatory actions added human safety or efficacy data. The literature did not change; the rules around it did.

FDA and U.S. status

• Current status (July 25, 2026): The "do not compound" prohibition has been lifted and PCAC has issued narrowly favorable 8–6–1 advisory recommendations for both forms; final FDA action has not been taken.
• FDA compounding category: Removed from Category 2 ("significant safety risks") effective ~April 22, 2026, following an April 15 Federal Register notice. Removal from Category 2 does not place a substance on the 503A bulk drug substances list and does not authorize compounding. (Federal Register; FDA 503A bulks-list process)
• PCAC recommendation: On July 23, 2026, PCAC voted 8 yes, 6 no, 1 abstain on BPC-157 free base and 8 yes, 6 no, 1 abstain on BPC-157 acetate, recommending inclusion for both forms. The exact question was whether each form should be placed on the 503A Bulks List. These recommendations are advisory: they do not approve BPC-157, authorize a specific product, or themselves complete FDA's process. (FDA voting questions; FDA-linked Day 1 broadcast)
• Next regulatory event: FDA's written meeting record and final determination. (FDA meeting page)
• WADA / sport: Prohibited at all times under S0 (non-approved substances), a material status for any tested athlete.

Risks and warning limits

• Known side effects (from the evidence that exists): The human evidence base is too small to characterize a side-effect profile with any confidence. This absence is itself the point — "no reported side effects" here means "almost no humans studied," not "proven safe."
• The concrete near-term risk: BPC-157 in circulation is compounded or research-grade material with no standardized identity, purity, or certificate of analysis. Consumer protections that exist for approved drugs do not exist here.
• Unknown unknowns: Long-term human safety, cancer signal, and interactions are simply unstudied.

What people are hearing

• What people report: Online communities talk about BPC-157 mainly for tendon and joint injuries and gut issues, often alongside TB-500. These are self-reports, not trial outcomes.
• Common misconceptions: "It was legalized in April" (no — a prohibition was lifted); "it's clinically proven for tendon repair" (no human tendon trial exists); "removed from Category 2 means the FDA vetted it as safe" (removal reflects a reclassification, not a safety finding).
• Product reality: Material sold under the name may be compounded or labeled "research use only." The name alone does not establish identity, purity, or quality.

What would change this answer

• FDA's written meeting record and final determination after the narrowly favorable 8–6–1 advisory recommendations.
• Enforcement direction — whether BPC-157 begins appearing in FDA warning letters independent of the GLP-1 crackdown (a signal the agency views Category 2 removal as housekeeping, not permission). (FDA Warning Letters database)
• Independent replication — whether any non-Zagreb group publishes controlled human data.
• Our coverage: The Peptide Current Issue No. 01 — "BPC-157 Isn't Legal Yet."

Sources and records

• Vasireddi et al., 2025 — Systematic review of BPC-157 in orthopaedic sports medicine
• ClinicalTrials.gov NCT02637284 — cancelled Phase 1 (PCO-02 / Bepecin)
• Federal Register — PCAC Notice of Meeting (April 16, 2026)
• FDA — PCAC meeting page, July 23–24, 2026
• FDA — exact PCAC voting questions (PDF)
• FDA-linked Day 1 archived broadcast — BPC-157 votes
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A

We do not link to vendors, telehealth prescribers, or supplement sellers.